Chardan Capital restated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $35.00 price target on the stock.
A number of other research analysts also recently issued reports on SLN. BMO Capital Markets cut their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a research report on Friday, May 9th. Finally, Morgan Stanley decreased their price objective on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.
Check Out Our Latest Research Report on SLN
Silence Therapeutics Trading Down 4.7%
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. On average, equities research analysts forecast that Silence Therapeutics will post -1.77 EPS for the current year.
Institutional Trading of Silence Therapeutics
Several large investors have recently bought and sold shares of SLN. Bank of America Corp DE raised its holdings in shares of Silence Therapeutics by 48,165.6% in the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock worth $3,434,000 after buying an additional 498,032 shares during the last quarter. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after acquiring an additional 2,793 shares during the period. Ameriprise Financial Inc. purchased a new position in Silence Therapeutics in the 4th quarter worth $113,000. Marshall Wace LLP lifted its position in Silence Therapeutics by 190.3% during the 4th quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock worth $3,364,000 after acquiring an additional 320,472 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after acquiring an additional 849,676 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- RH Stock Rockets on Surprise Profit and Tariff Shift
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- How to Calculate Return on Investment (ROI)
- Alphabet Enters a Bull Market: Is It Time to Buy?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.